Compare CSTL & CRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CSTL | CRF |
|---|---|---|
| Founded | 2007 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2019 | N/A |
| Metric | CSTL | CRF |
|---|---|---|
| Price | $32.44 | $7.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $46.67 | N/A |
| AVG Volume (30 Days) | 407.5K | ★ 1.1M |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 18.10% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.40 |
| Revenue | ★ $343,530,000.00 | $11,461,786.00 |
| Revenue This Year | $2.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.38 |
| Revenue Growth | ★ 10.15 | 6.53 |
| 52 Week Low | $14.59 | $5.70 |
| 52 Week High | $44.28 | $9.56 |
| Indicator | CSTL | CRF |
|---|---|---|
| Relative Strength Index (RSI) | 24.66 | 35.85 |
| Support Level | $38.20 | $7.65 |
| Resistance Level | $40.88 | $8.00 |
| Average True Range (ATR) | 1.98 | 0.09 |
| MACD | -1.10 | -0.03 |
| Stochastic Oscillator | 3.79 | 31.17 |
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.